Medexus Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 02 2021 - 7:30AM
Medexus Pharmaceuticals Inc. (“
Medexus” or the
“
Company”) (TSX: MDP) (OTCQX: MEDXF) today
announced that Ken d’Entremont, Chief Executive Officer of Medexus,
and Marcel Konrad, Chief Financial Officer of Medexus, will be
presenting at the H.C. Wainwright 23rd Annual Global Investment
Conference being held virtually between September 13-15, 2021.
Medexus’s presentation will be available on-demand to registered
attendees via the conference platform beginning Monday, September
13, 2021, at 7:00 AM Eastern Time.
The webcast can be accessed here and on the investor relation
section of the Medexus website at
https://www.medexus.com/en_US/investors. Management will be
participating in one-on-one meetings with qualified members of the
investor community throughout the conference.
About Medexus
Medexus is a leader in innovative rare disease treatment
solutions with a strong North American commercial
platform. From a foundation of proven best in class products
we are building a highly differentiated company with a portfolio of
innovative and high value orphan and rare disease products that
will underpin our growth for the next decade. The Company’s vision
is to provide the best healthcare products to healthcare
professionals and patients, through our core values of Quality,
Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals
is focused on the therapeutic areas of hematology, auto-immune
disease, and allergy. The Company’s leading products are: Rasuvo™
and Metoject®, a unique formulation of methotrexate (auto-pen and
pre-filled syringe) designed to treat rheumatoid arthritis and
other auto-immune diseases; IXINITY®, an intravenous recombinant
factor IX therapeutic for use in patients 12 years of age or older
with Hemophilia B – a hereditary bleeding disorder characterized by
a deficiency of clotting factor IX in the blood, which is necessary
to control bleeding; and Rupall®, an innovative prescription
allergy medication with a unique mode of action. The Company has
also licensed treosulfan, a preparative regimen for allogeneic
hematopoietic stem cell transplantation to be used in combination
with fludarabine, from medac GmbH for Canada and the United
States.
For more information, please contact:
Ken d’Entremont, Chief Executive OfficerMedexus Pharmaceuticals
Inc.Tel.: 905-676-0003E-mail: ken.dentremont@medexus.com
Marcel Konrad, Chief Financial OfficerMedexus Pharmaceuticals
Inc.Tel.: 312-548-3139E-mail: marcel.konrad@medexus.com
Investor Relations (U.S.):Crescendo Communications, LLCTel:
+1-212-671-1020Email: mdp@crescendo-ir.com
Investor Relations (Canada):Tina ByersAdelaide CapitalTel:
905-330-3275E-mail: tina@adcap.ca
Medexus Pharmaceuticals (TSX:MDP)
Historical Stock Chart
From Dec 2024 to Jan 2025
Medexus Pharmaceuticals (TSX:MDP)
Historical Stock Chart
From Jan 2024 to Jan 2025